PrEP Awareness, Interest, and Use among Women Who Inject Drugs in Seattle, Washington: A Mixed Methods Study
- PMID: 39899230
- PMCID: PMC12074869
- DOI: 10.1007/s10461-025-04646-6
PrEP Awareness, Interest, and Use among Women Who Inject Drugs in Seattle, Washington: A Mixed Methods Study
Abstract
Women who inject drugs (WWID) are disproportionately affected by HIV and experience multiple barriers to PrEP use. We conducted a mixed methods study to assess PrEP awareness, interest, and use, and determinants of PrEP utilization among WWID at three community sites in Seattle, Washington from March-May 2023. Participants were ≥ 18 years old, spoke English, identified as women, had a history of injecting drugs, and self-reported a negative or unknown HIV status. We describe survey participant characteristics (n = 30) by PrEP candidacy based on behaviors associated with HIV acquisition. We concurrently recruited 16 WWID for semi-structured interviews, which were analyzed using the Rapid Assessment Process. Survey and interview data were triangulated to enhance interpretations. Among 30 WWID, 25 (83%) were PrEP candidates, of whom 19 (76%) had heard about PrEP; only 2 (8%) were currently using PrEP. Among PrEP candidates, 13 (57%) reported interest in daily oral PrEP and almost half (n = 12, 48%) reported interest in injectable PrEP. Qualitative data revealed cursory PrEP knowledge and a strong interest in daily oral and injectable PrEP among those who perceived they were at risk for HIV. Several barriers to PrEP use were noted including housing instability, adherence challenges, limited perceived risk, and competing priorities like safety and substance use. While most WWID were aware of PrEP, qualitative data suggested significant misconceptions about PrEP, and many described complex, intersecting barriers to use. Our findings highlight the need for increased low-barrier, population-specific interventions to improve uptake and sustained use of PrEP among WWID.
Keywords: HIV; Injection drug use; PrEP; Transactional sex; Women.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors have no competing interests to declare that are relevant to the content of this article.
Similar articles
-
Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.Harm Reduct J. 2018 Nov 12;15(1):55. doi: 10.1186/s12954-018-0263-5. Harm Reduct J. 2018. PMID: 30419926 Free PMC article.
-
Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey.PLoS One. 2021 Feb 25;16(2):e0247352. doi: 10.1371/journal.pone.0247352. eCollection 2021. PLoS One. 2021. PMID: 33630909 Free PMC article. Clinical Trial.
-
Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention.Harm Reduct J. 2017 Jun 29;14(1):40. doi: 10.1186/s12954-017-0166-x. Harm Reduct J. 2017. PMID: 28662716 Free PMC article.
-
The HIV pre-exposure prophylaxis continuum of care among women who inject drugs: A systematic review.Front Psychiatry. 2022 Aug 26;13:951682. doi: 10.3389/fpsyt.2022.951682. eCollection 2022. Front Psychiatry. 2022. PMID: 36090369 Free PMC article.
-
Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis.AIDS Behav. 2019 Oct;23(10):2641-2653. doi: 10.1007/s10461-019-02573-x. AIDS Behav. 2019. PMID: 31297684 Free PMC article.
Cited by
-
"The Simplest Way to Go": An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP.AIDS Behav. 2025 Aug 6. doi: 10.1007/s10461-025-04833-5. Online ahead of print. AIDS Behav. 2025. PMID: 40767995
References
-
- Injection drug use. HIV. Centers for Disease Control and Prevention, March 16, 2022. Available at: https://www.cdc.gov/hiv/risk/drugs/index.html
-
- Des Jarlais DC, McKnight C, Feelemyer J, et al. Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001–2005 and 2011–2015. Drug Alcohol Depend 2018;185:391–397. doi: 10.1016/j.drugalcdep.2017.12.039. - DOI - PMC - PubMed
-
- Des Jarlais DC, Feelemyer JP, Modi SN, Arasteh K, Hagan H. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend 2012;124(1–2):95–107. doi: 10.1016/j.drugalcdep.2011.12.020. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
